Moleculin Biotech, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Walter V. Klemp (CEO) and Jonathan P. Foster (CFO) certified on August 13, 2026 that the Q2 2026 10-Q fairly presents the company's financial condition and results of operations, disclosure controls are effective, and no material weaknesses in internal control were identified. No specific dollar amounts, operational changes, or business transactions are disclosed in these boilerplate certification exhibits.
Why this rating
Standard Sarbanes-Oxley compliance filing. No new information about operations, financials, deals, or material changes. Routine quarterly requirement.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.